Author:
Zain Jasmine,Bar Merav,Safdar Amar
Reference211 articles.
1. Zain J, O’Connor O. Pralatrexate: basic understanding and clinical development. Expert Opin Pharmacother. 2010;11(10):1705–14.
2. O’Connor OA, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011;29(9):1182–9.
3. Strater SI, McDonald GB. In: Appelbaum FR, Forman SJ, Negrin RS, Blume KG, editors. Thomas’ hematopoietic cell transplantation. Wiley-Blackwell, Hoboken, NJ; 2009. p. 1434–55.
4. Tuncer HH, Rana N, Milani C, Darko A, Al-Homsi SA. Gastrointestinal and hepatic complications of hematopoietic stem cell transplantation. World J Gastroenterol. 2012;18(16):1851–60.
5. Malone FR, Leisenring WM, Storer BE, Lawler R, Stern JM, Aker SN, et al. Prolonged anorexia and elevated plasma cytokine levels following myeloablative allogeneic hematopoietic cell transplant. Bone Marrow Transplant. 2007;40(8):765–72.